146 related articles for article (PubMed ID: 35382656)
1. Stem signatures associating SOX2 antibody helps to define diagnosis and prognosis prediction with esophageal cancer.
Peng ZY; Wang QS; Li K; Chen SS; Li X; Xiao GD; Tang SC; Ren H; Wang Z; Sun X
Ann Med; 2022 Dec; 54(1):921-932. PubMed ID: 35382656
[TBL] [Abstract][Full Text] [Related]
2. Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer.
Chen SS; Li K; Wu J; Peng ZY; Wang ZD; Wang JC; Xu CW; Zhu CL; Li BC; Ren H; Tang SC; Sun X
J Cancer Res Clin Oncol; 2021 Jan; 147(1):223-233. PubMed ID: 32691153
[TBL] [Abstract][Full Text] [Related]
3. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
4. Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of esophageal cancer.
Qin JJ; Wang XR; Wang P; Ren PF; Shi JX; Zhang HF; Xia JF; Wang KJ; Song CH; Dai LP; Zhang JY
Asian Pac J Cancer Prev; 2014; 15(6):2635-40. PubMed ID: 24761876
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis.
Du XM; Wang LH; Chen XW; Li YX; Li YC; Cao YW
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):305-312. PubMed ID: 27376796
[TBL] [Abstract][Full Text] [Related]
6. Effect of neoadjuvant chemoradiotherapy on p53 and SOX2 protein expression in esophageal adenocarcinoma.
Suzuki L; Nieboer D; van Lanschot JJ; Spaander MC; Looijenga LH; Biermann K
Biomark Med; 2020 Jun; 14(9):785-793. PubMed ID: 32677456
[No Abstract] [Full Text] [Related]
7. Comprehensive Exploration to Identify Predictive DNA Markers of ΔNp63/SOX2 in Drug Resistance in Human Esophageal Squamous Cell Carcinoma.
Ooizumi Y; Kojima K; Igarashi K; Tanaka Y; Harada H; Yokota K; Kaida T; Ishii S; Tanaka T; Yokoi K; Nishizawa N; Washio M; Ushiku H; Katoh H; Kosaka Y; Mieno H; Hosoda K; Watanabe M; Katada C; Hiki N; Yamashita K
Ann Surg Oncol; 2019 Dec; 26(13):4814-4825. PubMed ID: 31529309
[TBL] [Abstract][Full Text] [Related]
8. Serum autoantibodies in the early detection of esophageal cancer: a systematic review.
Zhang H; Xia J; Wang K; Zhang J
Tumour Biol; 2015 Jan; 36(1):95-109. PubMed ID: 25433500
[TBL] [Abstract][Full Text] [Related]
9. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer.
Yi L; Huang P; Zou X; Guo L; Gu Y; Wen C; Wu G
Pharmacol Res; 2020 Nov; 161():105144. PubMed ID: 32810627
[TBL] [Abstract][Full Text] [Related]
10. Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
Kobold S; Tams S; Luetkens T; Cao Y; Sezer O; Bartels BM; Reinhard H; Templin J; Bartels K; Hildebrandt Y; Lajmi N; Marx A; Haag F; Bokemeyer C; Kröger N; Atanackovic D
Clin Dev Immunol; 2011; 2011():302145. PubMed ID: 22190969
[TBL] [Abstract][Full Text] [Related]
11. Seven tumor-associated autoantibodies as a serum biomarker for primary screening of early-stage non-small cell lung cancer.
Chen P; Lu W; Chen T
J Clin Lab Anal; 2021 Nov; 35(11):e24020. PubMed ID: 34555232
[TBL] [Abstract][Full Text] [Related]
12. Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma.
Zhou SL; Yue WB; Fan ZM; Du F; Liu BC; Li B; Han XN; Ku JW; Zhao XK; Zhang P; Cui J; Zhou FY; Zhang LQ; Fan XP; Zhou YF; Zhu LL; Liu HY; Wang LD
Dis Esophagus; 2014; 27(8):790-7. PubMed ID: 24147952
[TBL] [Abstract][Full Text] [Related]
13. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.
Du Q; Yu R; Wang H; Yan D; Yuan Q; Ma Y; Slamon D; Hou D; Wang H; Wang Q
Clin Respir J; 2018 Jun; 12(6):2020-2028. PubMed ID: 29356386
[TBL] [Abstract][Full Text] [Related]
14. SOX2 autoantibodies as noninvasive serum biomarker for breast carcinoma.
Sun Y; Zhang R; Wang M; Zhang Y; Qi J; Li J
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2043-7. PubMed ID: 22832207
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3.
Miller TJ; McCoy MJ; Hemmings C; Bulsara MK; Iacopetta B; Platell CF
Pathology; 2017 Dec; 49(7):721-730. PubMed ID: 29102042
[TBL] [Abstract][Full Text] [Related]
16. SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.
van Olphen S; Biermann K; Spaander MC; Kastelein F; Steyerberg EW; Stoop HA; Bruno MJ; Looijenga LH
Am J Gastroenterol; 2015 Oct; 110(10):1420-8. PubMed ID: 26323187
[TBL] [Abstract][Full Text] [Related]
17. The role of seven autoantibodies in lung cancer diagnosis.
Luo B; Mao G; Ma H; Chen S
J Thorac Dis; 2021 Jun; 13(6):3660-3668. PubMed ID: 34277058
[TBL] [Abstract][Full Text] [Related]
18. Sox2 induces tumorigenesis and angiogenesis of early-stage esophageal squamous cell carcinoma through secretion of Suprabasin.
Takahashi K; Asano N; Imatani A; Kondo Y; Saito M; Takeuchi A; Jin X; Saito M; Hatta W; Asanuma K; Uno K; Koike T; Masamune A
Carcinogenesis; 2020 Nov; 41(11):1543-1552. PubMed ID: 32055838
[TBL] [Abstract][Full Text] [Related]
19. Early detection of lung cancer by using an autoantibody panel in Chinese population.
Ren S; Zhang S; Jiang T; He Y; Ma Z; Cai H; Xu X; Li Y; Cai W; Zhou J; Liu X; Hu X; Zhang J; Yu H; Zhou C; Hirsch FR
Oncoimmunology; 2018; 7(2):e1384108. PubMed ID: 29308305
[TBL] [Abstract][Full Text] [Related]
20. Loss of CD44 and SOX2 expression is correlated with a poor prognosis in esophageal adenocarcinoma patients.
Honing J; Pavlov KV; Meijer C; Smit JK; Boersma-van Ek W; Karrenbeld A; Burgerhof JG; Kruyt FA; Plukker JT
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S657-64. PubMed ID: 24833101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
